Drug Notebook

FDA Alerts

    Dermatologic Toxicity
  • Dermatologic toxicities, related to panitumumab-induced blockade of epidermal growth factor (EGF) binding and subsequent epidermal growth factor receptor (EGFR)-mediated signaling pathways, reported in 89% of patients and were severe (grade 3 or 4) in 12% of patients receiving panitumumab monotherapy in controlled trials.
  • Manifested as dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures.
  • Severe dermatologic toxicities were complicated by infection (e.g., sepsis, septic death, abscesses requiring incision and drainage).
  • If severe dermatologic toxicities occur, withhold or discontinue panitumumab and monitor for inflammatory or infectious complications. (See Dermatologic Toxicity under Dosage and Administration and Dermatologic, Mucosal, and Ocular Toxicity under Cautions.)

    Infusion-related Reactions
  • Severe infusion-related reactions reported in about 1% of patients.
  • Manifested as anaphylactic reaction, bronchospasm, fever, chills, and/or hypotension.
  • Fatal infusion reactions not reported with panitumumab, but have occurred with other monoclonal antibody preparations.
  • If severe infusion-related effects occur, discontinue panitumumab immediately and permanently. (See Infusion-related Reactions under Dosage and Administration and under Cautions.)

Drug Info Tools
Pill Finder
Search by color, shape and markings. click here
Drug Interaction Checker
Check any 2 drugs for interactions. click here
Drug Compare
Compare any two drugs side by side. click here
Healthline Part D Plan Selector Medicare Part D
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
Advertisement
Marketplace
Licensed from
panitumumab
Page: 1 2 3 Next >
(pan i TUE moo mab)

What is the most important information I should know about panitumumab?

Before receiving this medication, tell your doctor if you have any allergies or breathing problems. You may not be able to receive panitumumab, or you may need a dosage adjustment or special tests during treatment.

Panitumumab may cause severe skin problems such as acne, itching, redness, skin rash, dryness, peeling, cracking, or oozing, and swelling or infection around your fingernails or toenails. This medication can also cause redness or irritation of your eyes or eyelids. More severe forms of skin problems can lead to widespread infection and possibly death. Seek emergency medical attention at the first sign of any skin rash.

Some people receiving a panitumumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, itchy, short of breath, or if you have a fever or chills during the injection.

The side effects of panitumumab may not appear when you first start using the medication. Severe skin or eye reactions may occur up to 2 weeks after the start of your treatment. These effects may not clear up for weeks or even months after you stop receiving panitumumab.

Avoid exposure to sunlight or artificial UV rays (sunlamps or tanning beds). Panitumumab can make your skin more sensitive to sunlight and sunburn may result. Use a sunscreen (minimum SPF 15) and wear protective clothing if you must be out in the sun.

This medication may affect a woman's fertility (ability to have children). You may also have irregular menstrual periods while receiving panitumumab.

What is panitumumab?

Panitumumab is a cancer medication. It interferes with the growth of cancer cells and slows their growth and spread in your body.

Panitumumab is used to treat metastatic colorectal cancer that has progressed after treatment with other chemotherapy.

Panitumumab may also be used for other purposes not listed in this medication guide.

Page: 1 2 3 Next >
Advertisement
Back to Top